©2019 by HALO Diagnostics

Imaging-guided Biopsies

Personalized Care and Guidance

MR-guided Biopsy

Real-time monitoring provides precision in prostate biopsy

This is a highly specific image-targeted biopsy technique, mpMRI aids in real-time detection of the tumor suspicious region prior to the biopsy and then a needle is used to sample only the suspicious area within the gland, sparing healthy tissue.

Unlike the conventional “poke and hope” approach in transrectal ultrasound-guided biopsy (TRUS), where biopsy cores are taken randomly without seeing the tumor within the prostate gland.

Imaging-guided biopsy versus ultrasound-guided biopsy

Specific targeting of tumor suspicious region instead of random sampling (TRUS biopsy can miss aggressive cancer lesions about 30-35% of the time)

Minimally invasive with fewer cores (3-4) instead of 12 core TRUS Bx

Reduced pain and damage to the rectal wall

Reduced chances of infection

Increased sensitivity of detecting aggressive lesions with decreased potential for detecting indolent disease.  This reduces overtreatment and prevents the psychological burden with misclassification of cancer stage

The transition from a “poke and hope” approach to precision in diagnosis 

Better spatial localization with specialized software to reach tumor suspicious regions otherwise difficult to reach with TRUS

TRUS Bx can underscore lesions due to its inherent random nature.  Aggressive cancer could be “skimmed” or completely missed. A low-grade tumor might be sampled while an aggressive one is completely missed.

Study shows MRI-guided biopsy is more accurate than ultrasound-guided biopsy  in detecting clinically significant prostate cancer

Targeted, less invasive and clinically significant detection

Conclusions from the clinical studies to compare the accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer suggest:

  • Nearly 27% fewer patients with elevated PSA levels had to get a prostate biopsy 

  • 5% fewer clinically insignificant cancers were detected 

  • 18% more cases of clinically significant cancer were identified

(Ref: Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham AP, Oldroyd R, Parker C, Emberton M. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017 Feb 25;389(10071):815-822. doi: 10.1016/S0140-6736(16)32401-1. Epub 2017 Jan 20. PubMed PMID: 28110982.